Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer.
Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghou F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S. Agarwal N, et al. Among authors: kimura a. Future Oncol. 2022 Mar;18(10):1185-1198. doi: 10.2217/fon-2021-1096. Epub 2022 Jan 17. Future Oncol. 2022. PMID: 35034502 Free article.
Cabozantinib in advanced renal cell carcinoma: A phase II, open-label, single-arm study of Japanese patients.
Tomita Y, Tatsugami K, Nakaigawa N, Osawa T, Oya M, Kanayama H, Nakayama Kondoh C, Sassa N, Nishimura K, Nozawa M, Masumori N, Miyoshi Y, Kuroda S, Tanaka S, Kimura A, Tamada S. Tomita Y, et al. Among authors: kimura a. Int J Urol. 2020 Nov;27(11):952-959. doi: 10.1111/iju.14329. Epub 2020 Aug 12. Int J Urol. 2020. PMID: 32789967 Free PMC article. Clinical Trial.
Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma.
Nakaigawa N, Tomita Y, Tamada S, Tatsugami K, Osawa T, Oya M, Kanayama H, Miura Y, Sassa N, Nishimura K, Nozawa M, Masumori N, Miyoshi Y, Kuroda S, Kimura A. Nakaigawa N, et al. Among authors: kimura a. Int J Clin Oncol. 2023 Mar;28(3):416-426. doi: 10.1007/s10147-022-02283-w. Epub 2023 Jan 3. Int J Clin Oncol. 2023. PMID: 36595123 Free PMC article. Clinical Trial.
Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine.
Handa H, Cheong JW, Onishi Y, Iida H, Kobayashi Y, Kim HJ, Chiou TJ, Izutsu K, Tsukurov O, Zhou X, Faessel H, Yuan Y, Sedarati F, Faller DV, Kimura A, Wu SJ. Handa H, et al. Among authors: kimura a. J Hematol Oncol. 2022 May 11;15(1):56. doi: 10.1186/s13045-022-01264-w. J Hematol Oncol. 2022. PMID: 35545778 Free PMC article. Clinical Trial.
Corrigendum to "Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor" [Biochem. Biophys. Rep. 21 (2020) 100726].
Hara T, Kimura A, Miyazaki T, Tanaka H, Morimoto M, Nakai K, Soeda J. Hara T, et al. Among authors: kimura a. Biochem Biophys Rep. 2020 Aug 20;24:100797. doi: 10.1016/j.bbrep.2020.100797. eCollection 2020 Dec. Biochem Biophys Rep. 2020. PMID: 33381660 Free PMC article.
Deglutition dynamics of patients with obstructive sleep apnea.
Ito S, Aoyagi Y, Hirata M, Ohashi M, Kagaya H, Inada H, Kimura A, Shikano K, Kaneko M, Okano T, Nakata S. Ito S, et al. Among authors: kimura a. Fujita Med J. 2024 May;10(2):43-48. doi: 10.20407/fmj.2023-010. Epub 2024 Feb 15. Fujita Med J. 2024. PMID: 38708078 Free PMC article.
3,156 results